• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Investigation of Factors That Affect the Quality of Life After a Stroke
Adv Exp Med Biol. 2023;1425:437-442. doi: 10.1007/978-3-031-31986-0_42.ABSTRACTStroke, as a disease, describes a group of disorders characterized by the presence of central nervous system symptoms either as a result of ischemia (ischemic stroke) or bleeding (hemorrhagic stroke). The appearance of a stroke results in a permanent physical or cognitive disability. The stroke incidence is the third cause of death after heart disease and cancer, and is the main cause of long-term disability.The effects of a stroke on a patient's daily life, and hence on his quality of life, are intense and long-lasting. These include memory pro...
Source: Cancer Control - August 15, 2023 Category: Cancer & Oncology Authors: Maria Malliarou Christina Tsionara Anna Patsopoulou Axilleas Bouletis Vasileios Tzenetidis Iokasti Papathanasiou Evangelia Kotrotsiou Mary Gouva Athanasios Nikolentzos Pavlos Sarafis Source Type: research

Novel contact-kinin inhibitor sylvestin targets thromboinflammation and ameliorates ischemic stroke
Cell Mol Life Sci. 2022 Apr 13;79(5):240. doi: 10.1007/s00018-022-04257-7.ABSTRACTIschemic stroke is a leading cause of death and disability worldwide. Increasing evidence indicates that ischemic stroke is a thromboinflammatory disease in which the contact-kinin pathway has a central role by activating pro-coagulant and pro-inflammatory processes. The blocking of distinct members of the contact-kinin pathway is a promising strategy to control ischemic stroke. Here, a plasma kallikrein and active FXII (FXIIa) inhibitor (sylvestin, contained 43 amino acids, with a molecular weight of 4790.4 Da) was first identified from fore...
Source: Cancer Control - April 13, 2022 Category: Cancer & Oncology Authors: Zhiye Zhang Chuanbin Shen Mingqian Fang Yajun Han Chengbo Long Weihui Liu Min Yang Ming Liu Dengdeng Zhang Qiqi Cao Xue Chen Yaqun Fang Qiumin Lu Zongliu Hou Yaxiong Li Zhenze Liu Xi Lei Heyu Ni Ren Lai Source Type: research

Left Atrial Appendage Occlusion in Patients With Atrial Fibrillation and  Cancer
CONCLUSIONS: Within our cohort, LAAO in cancer patients was achieved with good procedural success and offered a reduction in stroke at no increased bleeding risk similar to noncancer patients.PMID:37144110 | PMC:PMC10152198 | DOI:10.1016/j.jaccao.2022.10.016
Source: Cancer Control - May 5, 2023 Category: Cancer & Oncology Authors: Samuel A Shabtaie Nicholas Y Tan Robert C Ward Bradley R Lewis Eric H Yang David R Holmes Joerg Herrmann Source Type: research

Breast Cancer and Incident Cardiovascular Events. A Systematic Analysis at the Nationwide Level
CONCLUSIONS: In a large and contemporary analysis of female patients seen in French hospitals, women with history of breast cancer had higher risk of all-cause mortality, new onset heart failure and major bleeding compared to a matched cohort of women without breast cancer. In contrast, they have a reduced risk of cardiovascular mortality, MI, and stroke.PMID:35113450 | DOI:10.1111/eci.13754
Source: Clinical Breast Cancer - February 3, 2022 Category: Cancer & Oncology Authors: Ying X Gue Arnaud Bisson Alexandre Bodin Julien Herbert Gregory Y H Lip Laurent Fauchier Source Type: research

Cancers, Vol. 14, Pages 3049: Mortality and Major Cardiovascular Events among Patients with Multiple Myeloma: Analysis from a Nationwide French Medical Information Database
Conclusions: From a large nationwide database, we demonstrated that MM patients do not have a higher risk of CV death or even a lower risk of both MI and ischaemic stroke. Conversely, MM patients had a higher risk of both major and intracranial bleedings, highlighting the key issue of thromboprophylaxis in these patients.
Source: Cancers - June 21, 2022 Category: Cancer & Oncology Authors: Yves Cottin Mathieu Boulin Clara Doisy Morgane Mounier Denis Caillot Marie Lorraine Chretien Alexandre Bodin Julien Herbert Bernard Bonnotte Marianne Zeller Marc Maynadi é Laurent Fauchier Tags: Article Source Type: research

Comparative Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin Among Adults With Cancer and Atrial Fibrillation
CONCLUSIONS: Older adults with cancer and atrial fibrillation exposed to DOACs had similar risks of stroke and systemic embolism and major bleeding as those exposed to warfarin. Relative to warfarin, DOAC use was associated with a similar risk of cardiovascular death and a lower risk of all-cause death.PMID:36453260 | DOI:10.1161/CIRCOUTCOMES.122.008951
Source: Cancer Control - December 1, 2022 Category: Cancer & Oncology Authors: Hemalkumar B Mehta Huijun An Shirin Ardeshirrouhanifard Mukaila A Raji G Caleb Alexander Jodi B Segal Source Type: research

Vascular complications in glioma patients.
Abstract Vascular complications in patients with glioma most commonly include venous and arterial thromboembolism; however, treatment-induced vasculopathies are also problematic, especially in long-term survivors. The interactions between treatment such as radiation and chemotherapy, the coagulation cascade, endothelium, and regulators of angiogenesis are complex, drive glioma growth and invasion, and create common management problems in the clinic. We review the incidence of thrombotic complications in glioma, the biology of the coagulome as related to glioma progression, prevention and treatment of thrombosis, t...
Source: Clinical Genitourinary Cancer - March 9, 2016 Category: Cancer & Oncology Authors: Le Rhun E, Perry JR Tags: Handb Clin Neurol Source Type: research

Task Force Releases Recommendations on Aspirin to Prevent Colon Cancer, Heart Disease
By Stacy SimonRESOURCES: Aspirin and Cancer Prevention: What the Research Really Shows The United States Preventive Services Task Force (USPSTF) has published new recommendations about aspirin to help prevent cardiovascular disease (heart attacks and strokes) and colorectal cancer (commonly called colon cancer).The USPSTF says people who are ages 50-59 years, who have at least a 10% risk of developing cardiovascular disease within the next 10 years, and who have no increased risk for bleeding should take low-dose aspirin regularly to help prevent heart attack, stroke, and colon cancer. Candidates should also have a l...
Source: American Cancer Society :: News and Features - April 11, 2016 Category: Cancer & Oncology Tags: Colon/Rectum Cancer Source Type: news

Vascular complications in glioma patients.
Abstract Vascular complications in patients with glioma most commonly include venous and arterial thromboembolism; however, treatment-induced vasculopathies are also problematic, especially in long-term survivors. The interactions between treatment such as radiation and chemotherapy, the coagulation cascade, endothelium, and regulators of angiogenesis are complex, drive glioma growth and invasion, and create common management problems in the clinic. We review the incidence of thrombotic complications in glioma, the biology of the coagulome as related to glioma progression, prevention and treatment of thrombosis, t...
Source: Clinical Genitourinary Cancer - December 16, 2016 Category: Cancer & Oncology Authors: Le Rhun E, Perry JR Tags: Handb Clin Neurol Source Type: research

Efficacy and Safety of Rivaroxaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation and a History of Cancer: Observations from ROCKET AF.
Conclusion: In ROCKET AF, a history of cancer was associated with a higher risk of bleeding and non-cardiovascular death, but not ischemic events. The relative efficacy and safety of rivaroxaban compared with warfarin were not significantly different in patients with and without a history of cancer. The results of this study are exploratory and should be taken in context of the study population, which may not be generalizable to those with advanced malignancy. Further investigation is needed to understand optimal anticoagulation strategies in patients with AF and cancer. PMID: 30219887 [PubMed - as supplied by publisher]
Source: Clinical Genitourinary Cancer - September 14, 2018 Category: Cancer & Oncology Authors: Chen ST, Hellkamp AS, Becker RC, Berkowitz SD, Breithardt G, Fox KAA, Hacke W, Halperin JL, Hankey GJ, Mahaffey KW, Nessel CC, Piccini JP, Singer DE, Patel MR, Melloni C Tags: Eur Heart J Qual Care Clin Outcomes Source Type: research

Coronary Artery Bypass Grafting in Cancer Patients: Prevalence and Outcomes in the United States.
CONCLUSION: Among those undergoing CABG, the prevalence of comorbid cancer has steadily increased. Outside of major bleeding, these patients appear to share similar outcomes to those without cancer indicating that CABG utilization should be not be declined in cancer patients when otherwise indicated. Further research into the factors underlying the decision to pursue CABG in specific cancer sub-groups is needed. PMID: 32861331 [PubMed - in process]
Source: Clinical Prostate Cancer - August 31, 2020 Category: Cancer & Oncology Authors: Guha A, Dey AK, Kalra A, Gumina R, Lustberg M, Lavie CJ, Sabik JF, Addison D Tags: Mayo Clin Proc Source Type: research

Renal outcomes in valve-in-valve transcatheter versus redo surgical aortic valve replacement: A systematic review and meta-analysis
CONCLUSION: Renoprotective strategies should be put into place to prevent and reduce AKI incidence regardless of the treatment modality. Patients undergoing re-intervention for the aortic valve constitute a high-risk and frail population in which ViV-TAVR demonstrated it might be a feasible option for carefully selected patients. Long-term follow-up data and randomized control trials will be needed to evaluate mortality and morbidity outcomes between these 2 treatments.PMID:36040611 | DOI:10.1111/jocs.16890
Source: Cancer Control - August 30, 2022 Category: Cancer & Oncology Authors: Arian Arjomandi Rad Vinci Naruka Robert Vardanyan Mohammad Yousuf Salmasi Panagiotis T Tasoudis Simon Kendall Roberto Casula Thanos Athanasiou Source Type: research

Managing the Risks of Cardiac Therapy in Cancer Patients
The purpose of this review was to highlight the more commonly used cardiac medications that should be closely monitored or possibly discontinued during cancer therapy. Often, older cancer patients are taking multiple pharmacotherapy agents for the treatment or prevention of cardiac disease when they face decisions about cancer treatment. Concurrent administration of drugs can result either in increased toxicity or decreased efficacy of either therapy. The benefits of the cardiac medications must be weighed against the effects of cancer therapy, and the role of drug metabolism also must be considered. For example, the benef...
Source: Seminars in Oncology - April 1, 2013 Category: Cancer & Oncology Authors: Carol L. Chen, Rekha Parameswaran Tags: Marc L. Schwartz, ME, Guest Editor Source Type: research

Estimates of benefits and harms of prophylactic use of aspirin in the general population
Conclusions Prophylactic aspirin use for a minimum of 5 years at doses between 75 and 325 mg/day appears to have favourable benefit–harm profile; longer use is likely to have greater benefits. Further research is needed to determine the optimum dose and duration of use, to identify individuals at increased risk of bleeding, and to test effectiveness of Helicobacter pylori screening–eradication before starting aspirin prophylaxis.
Source: Annals of Oncology - December 17, 2014 Category: Cancer & Oncology Authors: Cuzick, J., Thorat, M. A., Bosetti, C., Brown, P. H., Burn, J., Cook, N. R., Ford, L. G., Jacobs, E. J., Jankowski, J. A., La Vecchia, C., Law, M., Meyskens, F., Rothwell, P. M., Senn, H. J., Umar, A. Tags: reviews Source Type: research

Pages: 1  2  3